Literature DB >> 6721984

Drug metabolite concentration-time profiles: influence of route of drug administration.

J B Houston, G Taylor.   

Abstract

In order to assess the contribution of an active metabolite to the overall pharmacological response following drug administration it is necessary to characterise the metabolite concentration-time profile. The influence of route of drug administration on metabolite kinetics has been investigated by computer simulation. Comparisons between simulated profiles and published concentration-time data have been carried out. A route dependence in metabolite concentration-time curves is readily apparent provided the metabolite kinetics are formation rate limited and the hepatic clearance of drug is greater than 25 l/h (medium to highly cleared). Oral drug administration produces a triphasic metabolite concentration-time profile whereas only two phases are discernable after intravenous drug administration. The magnitude of the difference in maximum metabolite concentration is directly proportional to the hepatic clearance of drug due to first-pass metabolite production. The route dependence in the shape of the metabolite concentration-time curves is most dramatic when the absorption and distribution of drug and the elimination of metabolite is rapid. A reduction in the rate of either of these processes alters the shape of the metabolite concentration-time profile such that the consequence of first-pass metabolite formation may be reduced.

Mesh:

Substances:

Year:  1984        PMID: 6721984      PMCID: PMC1463397          DOI: 10.1111/j.1365-2125.1984.tb02362.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  29 in total

1.  A method for the estimation of the fraction of a precursor that is converted to a metabolite in rat in vivo with phenacetin and acetaminophen.

Authors:  K S Pang; K Strobl; J R Gillette
Journal:  Drug Metab Dispos       Date:  1979 Nov-Dec       Impact factor: 3.922

Review 2.  Drug metabolite kinetics.

Authors:  J B Houston
Journal:  Pharmacol Ther       Date:  1981       Impact factor: 12.310

Review 3.  Drug metabolites in renal failure: pharmacokinetic and clinical implications.

Authors:  R K Verbeeck; R A Branch; G R Wilkinson
Journal:  Clin Pharmacokinet       Date:  1981 Sep-Oct       Impact factor: 6.447

4.  Metabolite pharmacokinetics: the area under the curve of metabolite and the fractional rate of metabolism of a drug after different routes of administration for renally and hepatically cleared drugs and metabolites.

Authors:  K S Pang
Journal:  J Pharmacokinet Biopharm       Date:  1981-08

5.  The effect of quinidine and its metabolites on the electrocardiogram and systolic time intervals: concentration--effect relationships.

Authors:  N H Holford; P E Coates; T W Guentert; S Riegelman; L B Sheiner
Journal:  Br J Clin Pharmacol       Date:  1981-02       Impact factor: 4.335

6.  Naphthoxylactic acid after single and long-term doses of propranolol.

Authors:  T Walle; E C Conradi; U K Walle; T C Fagan; T E Gaffney
Journal:  Clin Pharmacol Ther       Date:  1979-11       Impact factor: 6.875

7.  Interaction of phenobarbital with propranolol in the dog. 3. Beta blockade.

Authors:  S A Bai; F P Abramson
Journal:  J Pharmacol Exp Ther       Date:  1983-01       Impact factor: 4.030

8.  Presystemic metabolism of meperidine to normeperidine in normal and cirrhotic subjects.

Authors:  S M Pond; T Tong; N L Benowitz; P Jacob; J Rigod
Journal:  Clin Pharmacol Ther       Date:  1981-08       Impact factor: 6.875

9.  Meperidine disposition in man: influence of urinary pH and route of administration.

Authors:  R K Verbeeck; R A Branch; G R Wilkinson
Journal:  Clin Pharmacol Ther       Date:  1981-11       Impact factor: 6.875

10.  4-Hydroxypropranolol and its glucuronide after single and long-term doses of propranolol.

Authors:  T Walle; E C Conradi; U K Walle; T C Fagan; T E Gaffney
Journal:  Clin Pharmacol Ther       Date:  1980-01       Impact factor: 6.875

View more
  10 in total

1.  Physiological modeling of drug and metabolite: disposition of oxazepam and oxazepam glucuronides in the recirculating perfused mouse liver preparation.

Authors:  M V St-Pierre; D van den Berg; K S Pang
Journal:  J Pharmacokinet Biopharm       Date:  1990-10

2.  Structural identifiability of "first-pass" models.

Authors:  A Venot; E Walter; Y Lecourtier; A Raksanyi; L Chauvelot-Moachon
Journal:  J Pharmacokinet Biopharm       Date:  1987-04

3.  Primary, secondary, and tertiary metabolite kinetics.

Authors:  M V St-Pierre; X Xu; K S Pang
Journal:  J Pharmacokinet Biopharm       Date:  1988-10

4.  Drug metabolite kinetics: noncompartmental analysis.

Authors:  M Weiss
Journal:  Br J Clin Pharmacol       Date:  1985-06       Impact factor: 4.335

Review 5.  A review of metabolite kinetics.

Authors:  K S Pang
Journal:  J Pharmacokinet Biopharm       Date:  1985-12

6.  Mephenytoin stereoselective elimination in the rat: II. Comparison of mephenytoin stereoselective clearance during chronic intravenous and hepatic portal vein administration.

Authors:  S H Akrawi; P J Wedlund
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1989 Oct-Dec       Impact factor: 2.441

Review 7.  Rationalization and prediction of in vivo metabolite exposures: the role of metabolite kinetics, clearance predictions and in vitro parameters.

Authors:  Justin D Lutz; Yasushi Fujioka; Nina Isoherranen
Journal:  Expert Opin Drug Metab Toxicol       Date:  2010-09       Impact factor: 4.481

8.  Extent and variability of the first-pass elimination of adinazolam mesylate in healthy male volunteers.

Authors:  J C Fleishaker; H Friedman; S R Pollock
Journal:  Pharm Res       Date:  1991-02       Impact factor: 4.200

9.  The pharmacokinetics of timegadine and two of its metabolites after multiple oral dosing, and the effects of concomitant administration of ibuprofen.

Authors:  S George; A McBurney; J W Ward
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

10.  Population pharmacokinetics of terfenadine.

Authors:  R L Lalonde; D Lessard; J Gaudreault
Journal:  Pharm Res       Date:  1996-06       Impact factor: 4.200

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.